1月5日，A股以放量大涨拉开2026年序幕，日成交额增至2.57万亿元，赚钱效应良好，4185只个股收红，传媒、医药生物、电子、证券、大消费等均表现 亮眼。 受访人士表示，国际流动性宽松、美元贬值、人民币升值及国内政策利好共振，今日A股放量大涨，资金从低股息权重切换至高景气成长，市场风险偏好 显著提升。短期强势有望延续，可逢低关注脑机接口、半导体等新兴产业，同时警惕技术性回调、海外不确定性与行业分化风险。 沪指12连阳 A股新年开门红：沪指12连阳，收涨1.38%报4023.42点；创业板指涨2.85%报3294.55点，深证成指涨逾2%；科创50飙升4.4%，沪深300、上证50、北证50 齐涨约2%。 交易量较上一个交易日放大5016亿元，日成交额增至2.57万亿元。杠杆资金方面，截至去年12月31日，沪深京两融余额为2.54万亿元。 盘面上，半导体、存储芯片、电子设备制造等科技主线大涨，生物医药、医疗器械、人脑工程、AI制药爆发，短剧互动亦表现活跃；银行、石油天然 气、天然气、页岩气等板块回落。 31个申万一级行业中26个飘红，石油石化、银行等板块微跌，传媒板块大涨，蓝色光标、天下秀、引力传媒、三七互娱 ...

Group 1 - The closing price of Botao Bio (688767) on January 5 was 45.34 yuan, reaching the daily limit with a trading volume of 7.08 billion yuan and a turnover rate of 10.69% [1] - The stock was listed on the daily trading list due to a price increase of 15% at the close [1] - The top five trading departments accounted for a total transaction of 2.95 billion yuan, with a net selling amount of 583.98 million yuan [1][2] Group 2 - The main buying department was the Shanghai-Hong Kong Stock Connect, with a purchase amount of 413.97 million yuan [2] - The leading selling department was Dongwu Securities Co., Ltd. Zhejiang Branch, with a selling amount of 383.27 million yuan [2] - Overall, the stock experienced a net outflow of 43.82 million yuan in main funds on that day [2]

Group 1 - The medical device sector experienced a significant increase of 5.5% on January 5, with JinHao Medical leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable individual stock performances included JinHao Medical with a closing price of 38.23, up 20.03%, and BoTuo Bio with a closing price of 45.34, also up 20.01% [1] Group 2 - The medical device sector saw a net inflow of 1.678 billion yuan from institutional investors, while retail investors experienced a net outflow of 644 million yuan [2] - The top individual stock in terms of net inflow was AiPeng Medical, with a net inflow of 1.57 million yuan, representing 25.59% of its trading volume [3] - Conversely, major outflows were observed in stocks like MaiRui Medical, which had a net outflow of 91.39 million yuan from retail investors, accounting for 2.74% of its trading volume [3]

Group 1 - The A-share market opened positively in 2026, with the ChiNext Index leading the gains and the Shanghai Composite Index surpassing 4000 points, marking a twelve-day winning streak [1] - The commercial aerospace sector is experiencing significant activity, with multiple stocks hitting the daily limit up, including Leike Defense and China Satellite Communications [1] - China's space exploration initiatives are advancing, with plans for manned lunar missions and the Chang'e 7 mission aimed at finding water ice on the Moon [1] Group 2 - The brain-computer interface (BCI) sector is witnessing a surge, with individual stocks like Beiyikang hitting the daily limit up, reflecting a broader market trend [2] - Elon Musk's company Neuralink plans to begin large-scale production of BCI devices in 2026, which could revolutionize human-robot interaction and expand applications beyond medical needs [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034 [2] Group 3 - Goldman Sachs recommends overweighting Chinese stocks in 2026, predicting annual market growth of 15% to 20% for 2026 and 2027, driven by factors such as AI applications and the "going out" trend [2] - The current valuation of the Chinese stock market is significantly discounted compared to global peers, presenting potential investment opportunities [2]

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

Group 1 - The brain-computer interface (BCI) sector in A-shares experienced a strong surge on January 5, 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the 20% daily limit up [1] - The medical device ETF rose by 5.6%, while the Hong Kong medical sector also saw gains, with the Hang Seng Pharmaceutical ETF and Hong Kong Stock Connect Medical ETF increasing by 6% and 5.7%, respectively [1] - Elon Musk's Neuralink announced plans for large-scale production of BCI devices in 2026, marking a significant shift from clinical validation to commercial-scale production [1][3] Group 2 - In 2025, China approved 76 innovative drugs for market, surpassing the 48 approved in 2024, with total transaction amounts for innovative drug licensing exceeding $130 billion and over 150 transactions, both setting historical records [1] - The medical device ETF (562600) tracks the CSI Medical Device Index, with the medical device industry comprising 89% and BCI content at 23.14% [3] - The Hang Seng Pharmaceutical ETF (159892) has a scale of 5.564 billion yuan, with top-weighted stocks including BeiGene [3]

Core Viewpoint - The brain-computer interface (BCI) industry is experiencing rapid growth, driven by advancements in technology and supportive government policies, with significant developments expected by 2026 when large-scale production is set to begin [2][3]. Industry Developments - Neuralink plans to start mass production of BCI devices in 2026, utilizing nearly fully automated surgical processes [2]. - The BCI index in the A-share market rose by 9.37%, with over 20 stocks, including companies like Botao Bio and Sanbo Brain Science, hitting the daily limit [2]. - The National Healthcare Security Administration (NHSA) has issued guidelines for BCI rehabilitation charges, which has accelerated the industry's growth [2]. Policy Support - The 14th Five-Year Plan identifies BCI as one of six key future industries, with specific pricing projects established for both invasive and non-invasive BCI technologies [3]. - New regulations from the NHSA in September 2025 will facilitate the coding of innovative medical products, further promoting BCI clinical applications [3]. Technological Breakthroughs - China has made significant strides in invasive BCI technology, becoming the second country globally to enter clinical trials for invasive BCI systems [4]. - The "North Brain No. 1" GCP multi-center clinical trial, set to launch in October 2025, will be the first to implement a high-throughput, wireless, semi-invasive BCI system with over 100 channels [4]. Competitive Landscape - The BCI industry in China is competitive, with the potential to lead globally, as companies focus on serving downstream clients, including hospitals and patients [5]. - The BCI industry has established a complete supply chain, covering upstream materials and chips, midstream signal processing, and downstream applications in healthcare and consumer products [6]. Regulatory Focus - BCI products, especially invasive types, are classified as high-risk medical devices, necessitating strict regulatory oversight [8]. - Companies like Xiangyu Medical and Aipeng Medical are actively pursuing product registrations for various BCI applications, including rehabilitation and monitoring systems [8][9].

Market Overview - The Shanghai Composite Index closed at 4018.63 points, above the five-day moving average, with an increase of 1.25% [1] - The total trading volume of A-shares reached 24,812.35 billion yuan [1] Stocks Performance - A total of 1,955 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - BeiYikang (18.85% deviation rate, 29.98% increase, latest price 44.96 yuan) [1] - WeiSi Medical (15.01% deviation rate, 20.00% increase, latest price 58.08 yuan) [1] - ChengYiTong (14.78% deviation rate, 19.98% increase, latest price 23.06 yuan) [1] Additional Notable Stocks - Other stocks with significant performance include: - GuanHao Biological (14.72% deviation rate, 20.00% increase, latest price 16.62 yuan) [1] - DiNaiKe (14.64% deviation rate, 20.00% increase, latest price 17.76 yuan) [1] - MeiHao Medical (14.46% deviation rate, 20.00% increase, latest price 28.86 yuan) [1] Trading Metrics - The trading turnover rates for the top performing stocks vary, with BeiYikang at 12.85% and WeiSi Medical at 7.20% [1] - The five-day moving average prices for these stocks range from 14.49 yuan to 282.35 yuan [1][2]

1月5日，脑机接口板块领涨A股。截至发稿，板块涨幅超13%，个股方面，倍益康30CM涨停，三博脑 科、博拓生物、美好医疗、翔宇医疗等近20股涨停。 消息面上，马斯克日前在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备 进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。其最新技术的设备电极丝可 直接穿过硬脑膜，而无需将其切开。 据悉，Neuralink的产品重点仍集中在治疗神经系统疾病，包括瘫痪、肌萎缩、帕金森、老年痴呆和视力 障碍。 同时，国内医疗企业在该领域不断实现技术突破。三博脑科旗下的福建三博已帮助受试者偏瘫上肢恢复 自由抓握功能；"北脑二号"也有望在2026年进入临床验证。博拓生物参股公司的植入式脑深部神经刺激 系统已进入科研性临床，产品拟2026年末启动注册。 不仅如此，资本市场对该领域的投资也较为火热，据动脉橙数据库不完全统计，2025年1—11月，我国 脑机接口领域共完成24起融资，同比增长30%。 中信建投在研报中分析称，脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来 看若能实现增强人、并与AI和机器人融合，有望打开万亿 ...

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...